Effect of flouxetine versus citalopram on sexual dysfunction, serum oxytocin and prolactin levels in women

Sexual dysfunction, serum oxytocin and prolactin level in women with diagnosis of depression treated with flouxetine or citalopram

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12614000869673

Enrollment

Registered

2014-08-13

Start date

2013-02-21

Completion date

2014-01-08

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Sexual dysfunction is an important adverse drug reactions of selective serotonin reuptake inhibitor(SSRIs) drugs. In some limited animal studies sexual dysfunction has been related to changes in oxytocin and prolactin levels due to usage of SSRIs. Flouxetine can cause more suppression in oxytocin than citalopram and less suppression in prolactin than citalopram. It has been postulated that decrease in oxytocin and increase in prolactin is responsible for more sexual abnormality adverse effects by fluoxetine versus citalopram. In this study we have selected some depressed women who need to starting an SSRIs. We randomized depressed women to give either fluoxetine 20 mg/day or citalopram 20 mg/day. After 4 weeks we have determined sexual dysfunction and oxytocin and prolactin levels in both groups. Finally severity of sexual dysfunction and oxytocin and prolactin will be compare in two groups.

Interventions

Administration arm1:oral tablet of flouxetine 20 mg/day for 4 weeks or arm 2: oral tablet of citalopram 20 mg/day for 4 weeks both for treatment of major depressive disorder in women. Adherence monitoring will be done by counting tablet return by patients.

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

All women need to be experiencing symptoms of sexual dysfunction with diagnosis of depression between 18-45 years old in the psychosomatic clinic of Taleghani hospital(Tehran, Iran) with informed consent

Exclusion criteria

patients with renal failure or hepatic failure, pregnat or breast feeding women

Outcome results